Buserelin
Clinical data | |
---|---|
Trade names | Suprefact, others |
Other names | Etilamide; HOE-766; HOE-766A; ICI-123215; S-746766; D-Ser(tBu)6EA10-LHRH; 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-LHRH (pig) |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy category |
|
GnRH agonist; Antigonadotropin | |
ATC code | |
Legal status | |
Legal status |
|
chymotrypsin-like endopeptidase)[1] | |
Metabolites | Buserelin (1–5)[4] |
Elimination half-life | Intravenous: 50–80 min[5] Subcutaneous: 80 min[5] Intranasal: 1–2 hours[5] |
Excretion | Urine, bile[3][5] |
Identifiers | |
| |
JSmol) | |
| |
| |
(verify) |
Buserelin, sold under the brand name Suprefact among others, is a
Buserelin was first patented in 1974 and approved for medical use in 1985.
Medical uses
Buserelin is approved for the treatment of
Dosages
For prostate cancer, the dosage of buserelin by
Available forms
Buserelin is available in the form of a 1 mg/mL
Contraindications
Contraindications of buserelin include the following:[1][2]
- Hypersensitivity to buserelin or any of the other components of the medication (case reports of anaphylaxis exist)
- Prostate cancer that is not hormone-dependent(as there will be no benefit from testosterone suppression)
- Individuals who have undergone gonadectomy(as hormone levels will not be affected)
- teratogenic)
- Undiagnosed abnormal vaginal bleeding
Side effects
During the initial phase of the therapy, before GnRH receptors have been significantly
Overdose
Buserelin appears to be safe in the event of an
Pharmacology
Pharmacodynamics
Buserelin is a GnRH agonist, or an
With chronic administration of buserelin however, the GnRH receptor becomes
In men, approximately 95% of circulating testosterone is produced by the testes, with the remaining 5% being derived from the adrenal glands.[9] In accordance, GnRH analogues like buserelin can reduce testosterone levels by about 95% in men.[9][22] Sex hormone levels, including those of estradiol and progesterone, are similarly profoundly suppressed in premenopausal women.[10] The suppression of estradiol levels is 95% and progesterone levels are less than 1 ng/mL (normal range during the luteal phase approximately 10–20 ng/mL); the resulting levels are equivalent to those in postmenopausal women.[10][11]
Buserelin has been found to suppress testosterone levels in men with prostate cancer from 426 ng/dL to 28 ng/dL (by 93.4%) with 200 μg by subcutaneous injection once per day and from 521 ng/dL to 53 ng/dL (by 89.8%) with 400 μg by nasal spray once every 8 hours (1,200 μg/day total).[25] The difference in suppression may have been due to poor compliance.[25] A few small studies have also assessed the suppression of testosterone levels with buserelin nasal spray twice a day instead of three times a day.[26][27] One such study found that testosterone levels in men with prostate cancer were suppressed during treatment with buserelin from 332 ng/dL to 215 ng/dL (28.9% lower than controls) with 200 μg by nasal spray twice a day (400 μg/day total), from 840 ng/dL to 182 ng/dL (71.4% lower than controls) with 500 μg by nasal spray twice a day (1,000 μg/day total), and from 598 ng/dL to 126 ng/dL (80.4% lower than controls) with 50 μg by subcutaneous injection once a day.[26]
Pharmacokinetics
Buserelin is ineffective via
Chemistry
Buserelin is a
History
Buserelin was first described in 1976 and was introduced for medical use in 1984.[29][30] Intranasal buserelin was the first GnRH agonist demonstrated to achieve medical castration in humans.[31] This was initially observed via a marked decrease in circulating testosterone levels in a single patient in 1980.[31]
Society and culture
Generic names
Buserelin is the
Brand names
Buserelin is marketed by
Availability
Buserelin is marketed in the United Kingdom, Ireland, other European countries, Canada, New Zealand, and South Africa, as well as in Latin America, Asia, and elsewhere in the world.[8][14][15] It is not available in the United States or Australia.[8][14][34]
Research
The steroidal antiandrogen cyproterone acetate has been studied for blocking the testosterone flare at the start of buserelin therapy in men with prostate cancer.[35][36] While cyproterone acetate for two weeks eliminates the biological and biochemical signs of the flare, no benefits on prostate cancer outcomes were observed.[35]
Very low doses of buserelin nasal spray have been assessed for increasing testosterone levels and fertility in men with
See also
References
- ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac "Suprefact - Buserelin Acetate (Product Monograph)" (PDF). Sanofi Aventis. August 10, 2015. Archived (PDF) from the original on April 23, 2018. Retrieved December 17, 2017.
- ^ a b c d e f "Suprefact Depot 2 months and Suprefact Depot 3 months (Product Monograph)" (PDF). Sanofi Aventis. August 10, 2015. Archived (PDF) from the original on June 19, 2018. Retrieved December 17, 2017.
- ^ S2CID 195691965.
- ISBN 978-88-470-2186-0. Archivedfrom the original on 11 February 2022. Retrieved 17 December 2017.
- ^ a b c d e "Buserelin". Archived from the original on 2018-03-12. Retrieved 2017-12-17.
- ^ a b "Buserelin - Pharm-Sintez - AdisInsight". Archived from the original on 2017-12-24. Retrieved 2017-12-17.
- ^ S2CID 22639336.
- ^ ISBN 978-3-88763-075-1. Archivedfrom the original on 2017-03-12. Retrieved 2017-12-17.
- ^ ISBN 978-1-903737-08-8.
- ^ ISBN 978-0-7817-1750-2.
- ^ ISBN 978-0-9697978-0-7.
- ISBN 978-1-78262-732-6. Archivedfrom the original on 28 October 2021. Retrieved 6 January 2018.
- ISBN 978-3-527-60749-5. Archivedfrom the original on 2021-06-20. Retrieved 2020-09-19.
- ^ a b c d e f g h "Buserelin". Archived from the original on 2018-01-06. Retrieved 2017-12-17.
- ^ a b "Drug Product Database Online Query". 25 April 2012. Archived from the original on 29 October 2020. Retrieved 17 December 2017.
- ISBN 978-3-642-37250-6. Archivedfrom the original on 28 October 2021. Retrieved 6 January 2018.
- ISBN 978-1-84973-585-8. Archivedfrom the original on 11 February 2022. Retrieved 17 December 2017.
- ^ a b "CinnaGen: CinnaFact". Archived from the original on 2018-01-06. Retrieved 2017-12-17.
- from the original on 2022-02-11. Retrieved 2019-09-24.
- ^ a b c "Suprefact (buserelin acetate)". medbroadcast.com. Archived from the original on 2021-09-21. Retrieved 2021-09-21.
- ^ ISBN 978-1-4557-2881-7. Archivedfrom the original on 11 February 2022. Retrieved 6 January 2018.
- ^ PMID 3087785.
- ISBN 978-93-5090-404-6. Archivedfrom the original on 11 February 2022. Retrieved 17 December 2017.
- ISBN 978-0-85369-787-9. Archivedfrom the original on 2022-02-11. Retrieved 2017-12-17.
- ^ S2CID 10101250.
- ^ PMID 6800852.
- PMID 6411994.
- ISBN 978-3-319-52210-4. Archivedfrom the original on 28 October 2021. Retrieved 17 December 2017.
- S2CID 260086614.
- ISBN 978-0-08-058368-6. Archivedfrom the original on 11 February 2022. Retrieved 17 December 2017.
- ^ PMID 24825748.
- ^ ISBN 978-1-4757-2085-3. Archivedfrom the original on 12 March 2017. Retrieved 17 December 2017.
- ^ ISBN 978-94-011-4439-1. Archivedfrom the original on 12 March 2017. Retrieved 17 December 2017.
- ^ "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Archived from the original on 16 November 2016. Retrieved 17 December 2017.
- ^ ISBN 978-1-85317-422-3. Archivedfrom the original on 8 February 2021. Retrieved 25 December 2017.
- ISBN 978-3-11-085367-4.
- S2CID 24680327.
- PMID 19591988.
Further reading
- Roila F (1989). "Buserelin in the treatment of prostatic cancer". Biomedicine & Pharmacotherapy. 43 (4): 279–285. PMID 2506941.
- Trabant H, Widdra W, de Looze S (1990). "Efficacy and safety of intranasal buserelin acetate in the treatment of endometriosis: a review of six clinical trials and comparison with danazol". Progress in Clinical and Biological Research. 323: 357–382. PMID 2106146.
- Brogden RN, Buckley MM, Ward A (March 1990). "Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile". Drugs. 39 (3): 399–437. S2CID 195691965.